Alzheimer disease: From biomarkers to diagnosis

Revue Neurologique

Volumn 169, Issue 10, 2013, Pages 744-751

  Dubois, B ^a   Epelbaum, S ^a   Santos, A ^a   Di Stefano, F ^a   Julian, A ^a   Michon, A ^a   Sarazin, M ^b   Hampel, H ^c  

^a ICM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer; Biomarkers; CSF; Diagnosis; Neuro imaging

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE; TAU PROTEIN;

ALGORITHM; ALZHEIMER DISEASE; AMNESIA; ASYMPTOMATIC DISEASE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; INTERNATIONAL WORK GROUP CRITERIA; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY;

ALZHEIMER; BIOMARKERS; BIOMARQUEURS; CSF; DIAGNOSIS; DIAGNOSTIC; LCR; NEURO-IMAGERIE; NEURO-IMAGING;

ALZHEIMER DISEASE; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DEMENTIA; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; GENETIC ASSOCIATION STUDIES; HUMANS;

EID: 84884986064     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2013.07.016     Document Type: Conference Paper

References (61)

1. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 3 2011 270 279
2. F. Barkhof, T.M. Polvikoski, E.C. van Straaten, R.N. Kalaria, R. Sulkava, and H.J. Aronen The significance of medial temporal lobe atrophy: a post-mortem MRI study in the very old Neurology 69 15 2007 1521 1527 (Pubitemid 47537859)
3. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 10 2003 605 613 (Pubitemid 37162569)
4. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 3 2010 131 144
5. F.H. Bouwman, N.A. Verwey, M. Klein, A. Kok, M.A. Blankenstein, and J.D. Sluimer New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population Dement Geriatr Cogn Disord 30 1 2010 1 7
6. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 3 2007 186 191 (Pubitemid 46825511)
7. M. Brys, E. Pirraglia, K. Rich, S. Rolstad, L. Mosconi, and R. Switalski Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment Neurobiol Aging 30 5 2009 682 690
8. K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, and S.J. Teipel CSF phosphorylated-tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 Pt 11 2006 3035 3041 (Pubitemid 44684523)
9. N.J. Cairns, M.D. Ikonomovic, T. Benzinger, M. Storandt, A.M. Fagan, and A.R. Shah Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch Neurol 66 12 2009 1557 1562
10. M.C. Carrillo, C.C. Rowe, C. Szoeke, C.L. Masters, D. Ames, and T. O'Meara Research and standardization in Alzheimer's trials: reaching international consensus Alzheimers Dement 9 2 2013 160 168
11. H.F. Chiu, and L.C. Lam Relevance of outcome measures in different cultural groups - does one size fit all? Int Psychogeriatr 19 3 2007 457 466 (Pubitemid 46707420)
12. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 3 2011 275 283
13. C.A. de Jager, T.E. Honey, J. Birks, and G.K. Wilcock Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis Int J Geriatr Psychiatry 25 10 2010 988 997
14. M.J. de Leon, A. Convit, O.T. Wolf, C.Y. Tarshish, S. DeSanti, and H. Rusinek Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci U S A 98 19 2001 10966 10971 (Pubitemid 32878727)
15. L.C. de Souza, F. Lamari, S. Belliard, C. Jardel, C. Houillier, and R. De Paz Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias J Neurol Neurosurg Psychiatry 82 3 2011 240 246
16. B.S. Diniz, J.A. Pinto Junior, and O.V. Forlenza Do CSF total tau, phosphorylated-tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature World J Biol Psychiatry 9 3 2008 172 182
17. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 8 2007 734 746 (Pubitemid 47058377)
18. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 11 2010 1118 1127
19. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, and A.R. Shah Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans Ann Neurol 59 3 2006 512 519 (Pubitemid 43358072)
20. A.M. Fagan, M.A. Mintun, A.R. Shah, P. Aldea, C.M. Roe, and R.H. Mach Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease EMBO Mol Med 1 8-9 2009 371 380
21. A.M. Fagan, L.M. Shaw, C. Xiong, H. Vanderstichele, M.A. Mintun, and J.Q. Trojanowski Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology Arch Neurol 68 9 2011 1137 1144
22. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, and A. Wall PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 10 2008 1456 1465
23. M. Fotuhi, D. Do, and C. Jack Modifiable factors that alter the size of the hippocampus with ageing Nat Rev Neurol 8 4 2012 189 202
24. S. Galluzzi, C. Geroldi, R. Ghidoni, B. Paghera, G. Amicucci, and M. Bonetti The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment J Neurol 257 12 2010 2004 2014
25. C.J. Galton, K. Patterson, J.H. Xuereb, and J.R. Hodges Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuro-imaging and pathological study of 13 cases Brain 123 Pt 3 2000 484 498 (Pubitemid 30099534)
26. J.N. Giedd, P. Kozuch, D. Kaysen, A.C. Vaituzis, S.D. Hamburger, and J.J. Bartko Reliability of cerebral measures in repeated examinations with magnetic resonance imaging Psychiatry Res 61 2 1995 113 119
27. T. Grimmer, M. Riemenschneider, H. Forstl, G. Henriksen, W.E. Klunk, and C.A. Mathis Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 65 11 2009 927 934
28. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 3 2006 228 234 (Pubitemid 43238346)
29. J. Hort, A. Bartos, T. Pirttila, and P. Scheltens Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe Eur J Neurol 17 1 2010 90 96
30. M.D. Ikonomovic, E.E. Abrahamson, J.C. Price, R.L. Hamilton, C.A. Mathis, and W.R. Paljug Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study Acta Neuropathol 123 3 2012 433 447
31. M.C. Irizarry Biomarkers of Alzheimer disease in plasma NeuroRx 1 2 2004 226 234 (Pubitemid 46591884)
32. C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, and D. Harvey The Alzheimer's Disease Neuro-imaging Initiative (ADNI): MRI methods J Magn Reson Imaging 27 4 2008 685 691 (Pubitemid 351508080)
33. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman Relationships between biomarkers in aging and dementia Neurology 73 15 2009 1193 1199
34. K.A. Johnson, N.C. Fox, R.A. Sperling, and W.E. Klunk Brain imaging in Alzheimer disease Cold Spring Harb Perspect Med 2 4 2012 a006213
35. H.J. Kim, B.S. Ye, C.W. Yoon, H. Cho, Y. Noh, and G.H. Kim Effects of APOE epsilon4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment Neurobiol Aging 2013
36. J. Koivunen, N. Scheinin, J.R. Virta, S. Aalto, T. Vahlberg, and K. Nagren Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study Neurology 76 12 2011 1085 1090
37. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 3 2010 230 238
38. P. Lewczuk, G. Beck, H. Esselmann, R. Bruckmoser, R. Zimmermann, and M. Fiszer Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides Clin Chem 52 2 2006 332 334 (Pubitemid 43185505)
39. G. Li, I. Sokal, J.F. Quinn, J.B. Leverenz, M. Brodey, and G.D. Schellenberg CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 7 2007 631 639 (Pubitemid 47256004)
40. R.Y. Lo, A.E. Hubbard, L.M. Shaw, J.Q. Trojanowski, R.C. Petersen, and P.S. Aisen Longitudinal change of biomarkers in cognitive decline Arch Neurol 68 10 2011 1257 1266
41. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 4 2011 386 395 [e386]
42. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 4 2009 385 393
43. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 7 1984 939 944 (Pubitemid 14076461)
44. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 3 2011 263 269
45. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, and A.M. Goate Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch Neurol 66 12 2009 1469 1475
46. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Nagren Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 10 2009 754 760
47. R. Ossenkoppele, N. Tolboom, J.C. Foster-Dingley, S.F. Adriaanse, R. Boellaard, and M. Yaqub Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG-PET Eur J Nucl Med Mol Imaging 39 6 2012 990 1000
48. L. Rami, C. Sole-Padulles, J. Fortea, B. Bosch, A. Llado, and A. Antonell Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD Int J Geriatr Psychiatry 27 2 2012 127 134
49. M. Sarazin, C. Berr, J. De Rotrou, C. Fabrigoule, F. Pasquier, and S. Legrain Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study Neurology 69 19 2007 1859 1867 (Pubitemid 350071147)
50. N.S. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 1 2012 47 54
51. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuro-imaging initiative subjects Ann Neurol 65 4 2009 403 413
52. B.J. Snider, A.M. Fagan, C. Roe, A.R. Shah, E.A. Grant, and C. Xiong Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer-type Arch Neurol 66 5 2009 638 645
53. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 3 2011 280 292
54. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 4 2003 652 656 (Pubitemid 36246085)
55. T. Tapiola, I. Alafuzoff, S.K. Herukka, L. Parkkinen, P. Hartikainen, and H. Soininen Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 3 2009 382 389
56. N. Tolboom, W.M. van der Flier, M. Yaqub, R. Boellaard, N.A. Verwey, and M.A. Blankenstein Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding J Nucl Med 50 9 2009 1464 1470
57. L.A. van de Pol, F. Verhey, G.B. Frisoni, M. Tsolaki, P. Papapostolou, and F. Nobili White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study J Neurol Neurosurg Psychiatry 80 10 2009 1069 1074
58. N.A. Verwey, W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, and P.P. De Deyn A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 Pt 3 2009 235 240
59. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 7 2009 619 627
60. M. Wagner, S. Wolf, F.M. Reischies, M. Daerr, S. Wolfsgruber, and F. Jessen Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease Neurology 78 6 2012 379 386
61. D.A. Wolk, I.D. Grachev, C. Buckley, H. Kazi, M.S. Grady, and J.Q. Trojanowski Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology Arch Neurol 68 11 2011 1398 1403